Asset profile
Povetacicept
Protein / enzyme therapeutic
Evidence outlook · registrational
Primary Membranous Nephropathy: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-12-29.
Also in development:IgA NephropathyMyasthenia Gravis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
8 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 8 same-indication; 1 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Povetacicept: this drug | Phase 3 | Protein / enzyme therapeutic | — | ||
| Sparsentan (Filspari) | Approved | Small molecule | — | ||
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | ||
| Descartes-08 | Phase 3 | Cell therapy | — | ||
| IMVT-1402 | Phase 3 | Biologic (subtype unspecified) | — | ||
| IONIS-FB-LRx | Phase 2 | RNA / oligonucleotide | Complement factor B (CFB) | ||
| JADE101 | Phase 2 | Small molecule | — | ||
| Budoprutug | Phase 1/2 | Monoclonal antibody | — | ||
| ARO-CFB | Phase 1 | RNA / oligonucleotide | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (3)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.